$9.15
Revenue is up for the last 2 quarters, 11.21M → 11.68M (in $), with an average increase of 4.1% per quarter
Netprofit is down for the last 2 quarters, -47.56M → -128.78M (in $), with an average decrease of 170.7% per quarter
In the last 1 year, Seagen Inc has given 36.8% return, outperforming this stock by 89.6%
0.55%
Downside
Day's Volatility :4.11%
Upside
3.58%
38.47%
Downside
52 Weeks Volatility :71.38%
Upside
53.48%
Period | CureVac | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 5.79% | 0.3% | -6.7% |
6 Months | 30.95% | -6.1% | -3.7% |
1 Year | -51.38% | -4.8% | -6.3% |
3 Years | -83.65% | 23.8% | 26.9% |
Market Capitalization | 2.1B |
Book Value | $2.74 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.58 |
Wall Street Target Price | 16.43 |
Profit Margin | 0.0% |
Operating Margin TTM | -335.72% |
Return On Assets TTM | -14.02% |
Return On Equity TTM | -40.77% |
Revenue TTM | 67.4M |
Revenue Per Share TTM | 0.36 |
Quarterly Revenue Growth YOY | -71.6% |
Gross Profit TTM | -91.5M |
EBITDA | -209.6M |
Diluted Eps TTM | -1.58 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.17 |
EPS Estimate Next Year | -0.71 |
EPS Estimate Current Quarter | -0.34 |
EPS Estimate Next Quarter | -0.37 |
What analysts predicted
Upside of 79.56%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 14.7M | - |
Net Income | -81.5M | - |
Net Profit Margin | -553.5% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 19.5M | ↑ 35.31% |
Net Income | -111.9M | ↑ 40.19% |
Net Profit Margin | -573.46% | ↓ 19.96% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 60.1M | ↑ 180.61% |
Net Income | -158.8M | ↑ 29.29% |
Net Profit Margin | -264.21% | ↑ 309.25% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 116.6M | ↑ 110.74% |
Net Income | -466.3M | ↑ 218.86% |
Net Profit Margin | -399.76% | ↓ 135.55% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 72.2M | ↓ 34.54% |
Net Income | -266.8M | ↓ 39.51% |
Net Profit Margin | -369.37% | ↑ 30.39% |
Q3 FY21 | Q/Q Change | |
---|---|---|
Revenue | 34.0M | ↑ 31.01% |
Net Income | -166.7M | ↓ 5.28% |
Net Profit Margin | -490.88% | ↑ 188.09% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 46.7M | ↑ 40.51% |
Net Income | -2.2M | ↓ 98.66% |
Net Profit Margin | -4.7% | ↑ 486.18% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 27.2M | ↓ 40.88% |
Net Income | -16.8M | ↑ 679.6% |
Net Profit Margin | -61.93% | ↓ 57.23% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 21.0M | ↓ 17.34% |
Net Income | -60.2M | ↑ 281.53% |
Net Profit Margin | -285.83% | ↓ 223.9% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 11.0M | ↓ 44.35% |
Net Income | -46.8M | ↓ 17.39% |
Net Profit Margin | -424.26% | ↓ 138.43% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 12.5M | ↑ 4.25% |
Net Income | -138.0M | ↑ 170.74% |
Net Profit Margin | -1.1K% | ↓ 677.49% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 143.8M | - |
Total Liabilities | 107.1M | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 146.3M | ↑ 3.95% |
Total Liabilities | 194.3M | ↑ 85.33% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.9B | ↑ 1057.06% |
Total Liabilities | 984.0M | ↑ 361.31% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↓ 23.36% |
Total Liabilities | 532.0M | ↓ 41.28% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 921.8M | ↓ 25.71% |
Total Liabilities | 350.5M | ↓ 30.34% |
Q3 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 1.9B | ↓ 7.66% |
Total Liabilities | 1.1B | ↑ 0.22% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↓ 30.36% |
Total Liabilities | 532.0M | ↓ 51.46% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.1B | ↓ 11.36% |
Total Liabilities | 392.7M | ↓ 25.11% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 967.2M | ↓ 9.82% |
Total Liabilities | 316.1M | ↓ 13.98% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 895.0M | ↓ 1.65% |
Total Liabilities | 280.7M | ↓ 5.65% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 921.8M | ↓ 5.5% |
Total Liabilities | 350.5M | ↑ 14.6% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -84.8M | - |
Investing Cash Flow | -4.9M | - |
Financing Cash Flow | -128.1K | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -97.4M | ↑ 17.34% |
Investing Cash Flow | 31.6M | ↓ 760.91% |
Financing Cash Flow | 76.1M | ↓ 60795.54% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 642.6M | ↓ 700.72% |
Investing Cash Flow | -55.7M | ↓ 260.65% |
Financing Cash Flow | 1.0B | ↑ 1106.01% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -830.3M | ↓ 240.34% |
Investing Cash Flow | -144.8M | ↑ 182.5% |
Financing Cash Flow | 390.7M | ↓ 57.92% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -207.3M | ↓ 33.47% |
Investing Cash Flow | -39.2M | - |
Financing Cash Flow | -38.0M | ↑ 9057.1% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -152.4M | ↓ 25.43% |
Investing Cash Flow | -19.2M | ↓ 50.33% |
Financing Cash Flow | -513.5K | ↓ 98.63% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -67.6M | ↓ 52.63% |
Investing Cash Flow | -28.8M | ↑ 60.2% |
Financing Cash Flow | 4.0M | ↓ 941.09% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -35.3M | ↓ 44.46% |
Investing Cash Flow | -27.4M | ↑ 1.14% |
Financing Cash Flow | 26.0M | ↑ 584.0% |
Sell
Neutral
Buy
CureVac is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() CureVac | 30.57% | 30.95% | -51.38% | -83.65% | -83.65% |
![]() Moderna, Inc. | -5.37% | -27.09% | -13.14% | 105.27% | 578.71% |
![]() Regeneron Pharmaceuticals, Inc. | -10.19% | -1.57% | 8.99% | 18.23% | 144.36% |
![]() Seagen, Inc. | -2.85% | 64.85% | 42.61% | 23.08% | 248.38% |
![]() Vertex Pharmaceuticals Incorporated | -4.35% | 4.32% | 22.83% | 14.6% | 112.57% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() CureVac | NA | NA | NA | -1.17 | -0.41 | -0.14 | 0.0 | 2.74 |
![]() Moderna, Inc. | 11.28 | 11.28 | 0.0 | -1.96 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 20.02 | 20.02 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 27.02 | 27.02 | 0.41 | 14.64 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() CureVac | Buy | $2.1B | -83.65% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $48.2B | 578.71% | 11.28 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $79.5B | 144.36% | 20.02 | 33.81% |
![]() Seagen, Inc. | Hold | $36.5B | 248.38% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $85.7B | 112.57% | 27.02 | 35.4% |
T. Rowe Price Associates, Inc.
Citadel Advisors Llc
Bill & Melinda Gates Foundation
Balyasny Asset Management LLC
Camber Capital Management LLC
BlackRock Inc
CureVac’s price-to-earnings ratio stands at None
Read MoreCureVac N.V. operates as a global clinical-stage biopharmaceutical company. The Company focuses on developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. CureVac serves customers worldwide.
Organization | CureVac |
Employees | 904 |
CEO | Dr. Franz-Werner Haas L.L.M., LL.M., LLD, Ph.D. |
Industry | Health Technology |
VanEck Vectors Semiconductor ETF
$147.36
+4.91%
Trex Co. Inc.
$52.93
+0.55%
Azenta Inc
$42.67
+2.79%
International Game Technology
$24.89
+1.01%
Rambus Inc.
$66.52
+5.19%
Piper Jaffray Cos
$129.84
+1.8%
Enlight Renewable Energy Ltd
$18.10
+0.5%
Artisan Partners Asset Management Inc.
$32.80
+0.68%
Grupo Aeroportuario del Sureste, SABdeCV
$283.41
+1.33%